CEL-SCI Announces Bought Deal Offering
Cel-Sci Corporation (CVM)
NASDAQ:AMEX Investor Relations:
cel-sci.com/investor_relations.html
Company Research
Source: Business Wire
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced today that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 500,000 shares of common stock of the Company, at a price to the public of $12.22 per share (the “Public Price”), representing a 5% discount to the closing price per share. The closing of the offering is expected to occur on or about March 26, 2020, subject to customary closing conditions.Aegis Capital Corp. is acting as the sole book-running manager for the offering.The Company also has granted to the underwriter a 45-day option to purchase up to 15% of the offering at the Public Price. The use of proceeds will be to fund the continued development of Multikine, LEAPS and for other general corporate purposes.The shares of common stock described above are being offered by CEL-SCI pursua
Show less
Read more
Impact Snapshot
Event Time:
CVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVM alerts
High impacting Cel-Sci Corporation news events
Weekly update
A roundup of the hottest topics
CVM
News
- CEL-SCI Co. (NYSE: CVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025Business Wire
- CEL-SCI files to sell 1M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsBusiness Wire
- CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerBusiness Wire
CVM
Earnings
- 8/14/24 - Miss
CVM
Sec Filings
- 11/15/24 - Form 8-K
- 11/13/24 - Form 8-K
- 11/8/24 - Form EFFECT
- CVM's page on the SEC website